Dr. Kate Broderick - Chief Innovation Officer Maravai

Life Science Success

In this episode of Life Science Success, my guest is Dr. Kate Broderick. Dr. Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery fields. She also actively works with teams at TriLink BioTechnologies, a Maravai company, to advance its global reagents and manufacturing services.

• Dr. Kate Broderick's Background: Originally from Scotland, Kate Broderick's academic journey began with using animals as models for human diseases. Her passion lies at the intersection of science and clinical application, leading her to focus on DNA therapeutics and drug delivery fields in the United States, particularly after her postdoctoral work at UCSD.
• Focus on DNA and RNA Technologies: Dr. Broderick is motivated by the fundamental roles of DNA and RNA in medicine. She discusses the potential of these molecules to revolutionize treatments, vaccines, and therapies, foreseeing a future where new medical solutions are developed using these technologies.
• Career Development and Innovation: Throughout her career, Dr. Broderick has embraced various roles beyond her scientific training, including clinical development and finance, which have enriched her understanding of product development and corporate strategy within biotech startups.
• Role as Chief Innovation Officer at Maravai: In her current role, Dr. Broderick emphasizes the importance of innovation in staying ahead in the fast-paced field of life sciences. She discusses fostering collaborative environments for scientists, integrating client needs into R&D, and focusing on structured innovation to drive the company's mission forward.
• Concerns and Future Outlook: Dr. Broderick expresses concerns about vaccine hesitancy and misinformation, emphasizing the need for better communication in the scientific community. She is excited about the future of nucleic acid medicines, predicting significant advancements in treating various diseases and developing new vaccines within the next decade.